DE69320389T2 - Verfahren zur Herstellung des Inhibitors für die Komplexbildung des Gewebefaktors - Google Patents

Verfahren zur Herstellung des Inhibitors für die Komplexbildung des Gewebefaktors

Info

Publication number
DE69320389T2
DE69320389T2 DE69320389T DE69320389T DE69320389T2 DE 69320389 T2 DE69320389 T2 DE 69320389T2 DE 69320389 T DE69320389 T DE 69320389T DE 69320389 T DE69320389 T DE 69320389T DE 69320389 T2 DE69320389 T2 DE 69320389T2
Authority
DE
Germany
Prior art keywords
tfpi
inclusion bodies
purification
exchange chromatography
sulfonate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69320389T
Other languages
German (de)
English (en)
Other versions
DE69320389D1 (de
Inventor
Judith Arlene St Louis Missouri 63021 Diaz-Collier
Mark Edward St Charles Missouri 63304 Gustafson
Tze-Chein St Louis Missouri 63021 Wun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Monsanto Co
Original Assignee
Monsanto Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Monsanto Co filed Critical Monsanto Co
Application granted granted Critical
Publication of DE69320389D1 publication Critical patent/DE69320389D1/de
Publication of DE69320389T2 publication Critical patent/DE69320389T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69320389T 1992-03-02 1993-03-01 Verfahren zur Herstellung des Inhibitors für die Komplexbildung des Gewebefaktors Expired - Fee Related DE69320389T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/844,297 US5212091A (en) 1992-03-02 1992-03-02 Method of producing tissue factor pathway inhibitor

Publications (2)

Publication Number Publication Date
DE69320389D1 DE69320389D1 (de) 1998-09-24
DE69320389T2 true DE69320389T2 (de) 1999-03-11

Family

ID=25292320

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69320389T Expired - Fee Related DE69320389T2 (de) 1992-03-02 1993-03-01 Verfahren zur Herstellung des Inhibitors für die Komplexbildung des Gewebefaktors

Country Status (7)

Country Link
US (1) US5212091A (enExample)
EP (1) EP0559632B1 (enExample)
JP (1) JP3333846B2 (enExample)
AT (1) ATE169957T1 (enExample)
CA (1) CA2090650C (enExample)
DE (1) DE69320389T2 (enExample)
DK (1) DK0559632T3 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5378614A (en) * 1989-08-18 1995-01-03 Novo Nordisk A/S Vector and method for making tissue factor pathway inhibitor (TFPI) analogues in yeast
US5849703A (en) * 1990-08-27 1998-12-15 G. D. Searle & Co. Pre-formed anticoagulant heparin/TFPI complexes
US5212091A (en) 1992-03-02 1993-05-18 Monsanto Company Method of producing tissue factor pathway inhibitor
GB9215541D0 (en) 1992-07-22 1992-09-02 Celltech Ltd Protein expression system
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
US5552300A (en) * 1994-01-13 1996-09-03 T Cell Sciences, Inc. T cell antigen receptor V region proteins and methods of preparation thereof
US5824644A (en) * 1994-07-07 1998-10-20 G. D. Searle & Co. Method of attenuating arterial stenosis
US5589359A (en) * 1994-08-05 1996-12-31 Chiron Corporation Chimeric proteins
DE69528591T2 (de) * 1994-08-05 2003-02-20 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Herstellung des inhibitors fuer die komplexbildung des gewebefaktors
US5914316A (en) * 1994-12-16 1999-06-22 Washington University Method of inhibiting intimal hyperplasia
JPH11514334A (ja) * 1995-06-07 1999-12-07 チロン コーポレーション タンパク質の可溶化、精製、および再生の方法
US6242414B1 (en) 1995-06-07 2001-06-05 Chiron Corporation Regulation of cytokine synthesis and release
AU2003200506B2 (en) * 1995-06-07 2007-01-18 G.D. Searle Llc Method of solubilizing, purifying and refolding protein and compositions comprising proteins and solubilizing agents
US5885781A (en) * 1995-06-07 1999-03-23 Chiron Corporation Regulation of cytokine synthesis and release
US20030199450A1 (en) * 2001-04-27 2003-10-23 Chiron Corporation Regulation of cytokine synthesis and release
US5772629A (en) * 1995-10-23 1998-06-30 Localmed, Inc. Localized intravascular delivery of TFPI for inhibition of restenosis in recanalized blood vessels
US5824660A (en) * 1996-06-10 1998-10-20 G. D. Searle & Co. Method of inhibiting glomerulonephritis
US6214333B1 (en) 1997-07-08 2001-04-10 Texas Heart Institute Vasoprotective recombinant adenovirus vector containing a human TFPI gene
AU781717B2 (en) * 1998-04-24 2005-06-09 Csl Behring Gmbh Process for the preparation in pure form of the protease activating blood clotting factor VII, its proenzyme or mixture of both proteins by means of ion-exchange chromatography
US6743600B1 (en) 1999-04-30 2004-06-01 Monsanto Technologies Llc Method of removing N-terminal alanine residues from polypeptides with Aeromonas aminopeptidase
US6794159B1 (en) 1999-04-30 2004-09-21 Pharmacia Corporation Method of removing n-terminal alanine residues from polypeptides with aeromonas aminopeptidase
DE19937218A1 (de) * 1999-08-06 2001-02-08 Aventis Behring Gmbh Verfahren zur Reindarstellung der den Blutgerinnungsfaktor VII aktivierenden Protease, ihres Proenzyms oder eines Gemisches beider Proteine mittels Affinitätschromatographie
EA200400549A1 (ru) * 2001-10-15 2005-02-24 Чирон Корпорейшн Лечение сепсиса введением малых доз ингибитора пути тканевого фактора (tfpi)
ATE528014T1 (de) 2002-06-07 2011-10-15 Dyax Corp Polypeptid mit modifizierten kunitz domains
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
JP4522997B2 (ja) * 2003-08-13 2010-08-11 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Ｔｆｐｉおよびｔｆｐｉアナログを精製するための改良された方法
EP1729791A2 (en) * 2004-03-17 2006-12-13 Chiron Corporation Treatment of severe community-acquired pneumonia by admistration of tissue factor pathway inhibitor (tfpi)
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
CN101262880A (zh) * 2005-06-24 2008-09-10 德拉格雷丘尔公司 在影响呼吸道的炎症病状中气道施用组织因子途径抑制物
US20080090760A2 (en) * 2005-12-09 2008-04-17 Todd Hembrough Compositions and Methods for Inhibiting Cellular Proliferation
LT1981519T (lt) 2005-12-29 2018-04-25 Dyax Corp. Proteazės slopinimas
WO2009026334A2 (en) * 2007-08-21 2009-02-26 Genzyme Corporation Treatment with kallikrein inhibitors
KR101179171B1 (ko) 2008-08-14 2012-09-03 주식회사 운화 산삼 또는 인삼을 포함한 인삼류의 형성층 유래 식물줄기세포주를 유효성분으로 함유하는 간질환의 예방 또는 치료용 조성물
JP2013516389A (ja) * 2009-01-06 2013-05-13 ダイアックス コーポレーション カリクレイン阻害剤による粘膜炎治療
US8088599B2 (en) * 2009-02-06 2012-01-03 Fudan University Nucleic acids encoding genetically modified tissue factor pathway inhibitor (TFPI) and method of making the same
ES2905545T3 (es) 2010-01-06 2022-04-11 Takeda Pharmaceuticals Co Proteínas de unión a calicreína plasmática
IL269565B2 (en) 2011-01-06 2024-06-01 Dyax Corp Plasma kallikrein binding proteins
EP3122782A4 (en) 2014-03-27 2017-09-13 Dyax Corp. Compositions and methods for treatment of diabetic macular edema
CN116077648A (zh) 2015-12-11 2023-05-09 武田药品工业株式会社 血浆激肽释放酶抑制剂及其治疗遗传性血管性水肿发作的用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4421685A (en) * 1980-03-27 1983-12-20 Eli Lilly And Company Process for producing an insulin
US4656249A (en) * 1982-06-10 1987-04-07 Howard Florey Institute Of Experimental Physiology And Medicine Peptides with relaxin activity
US4511502A (en) * 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4512922A (en) * 1982-12-22 1985-04-23 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
DE3537708A1 (de) * 1985-10-23 1987-04-23 Boehringer Mannheim Gmbh Verfahren zur aktivierung von t-pa nach expression in prokaryonten
US4734362A (en) * 1986-02-03 1988-03-29 Cambridge Bioscience Corporation Process for purifying recombinant proteins, and products thereof
US4966852A (en) * 1987-07-23 1990-10-30 Monsanto Company DNA clone of human tissue factor inhibitor
US4923967A (en) * 1988-09-26 1990-05-08 Eli Lilly And Company Purification and refolding of recombinant proteins
DE3832898A1 (de) * 1988-09-28 1990-04-12 Boehringer Mannheim Gmbh Praeparat von in prokaryonten exprimiertem plasminogenaktivator
US5212091A (en) 1992-03-02 1993-05-18 Monsanto Company Method of producing tissue factor pathway inhibitor
KR950701820A (ko) * 1992-06-11 1995-05-17 로저 에이. 윌리암스 패혈증 및 패혈증-연관 옹고장애의 예방 및 치료(prophylaxs and treatment of sepsis and sepsis-associated coagulation disorders)

Also Published As

Publication number Publication date
DE69320389D1 (de) 1998-09-24
JP3333846B2 (ja) 2002-10-15
CA2090650A1 (en) 1993-09-03
CA2090650C (en) 2008-01-29
US5212091A (en) 1993-05-18
DK0559632T3 (da) 1998-10-26
EP0559632A3 (enExample) 1995-03-29
EP0559632A2 (en) 1993-09-08
ATE169957T1 (de) 1998-09-15
JPH07274968A (ja) 1995-10-24
EP0559632B1 (en) 1998-08-19

Similar Documents

Publication Publication Date Title
DE69320389T2 (de) Verfahren zur Herstellung des Inhibitors für die Komplexbildung des Gewebefaktors
DE69004966T2 (de) Antikoagulierendes protein.
DE3586750T2 (de) Rekombinante fusionsproteine.
DE69202049T2 (de) Verfahren zur reinigung von intaktem und korrekt gefaltetem igf-i.
DE69125810T2 (de) Verfahren zur enzymatischen herstellung von basischen fibroblasten-wachstumsfaktors
DE68929387T2 (de) Interleukin-1-Inhibitoren
DE3686654T2 (de) Verfahren zur isolierung rekombinanter polypeptide in biologisch aktiver form.
DE69030582T2 (de) Herstellung eines rekombinanten menschlichen interleukin-1-hemmers
EP0428267B2 (en) Erythropoietin isoforms
DE3688663T2 (de) Reinigung und Aktivierung von Proteinen aus unlöslichen Einschlussteilchen.
Baglioni et al. Abnormal human haemoglobins V. Chemical investigation of haemoglobins A, G, C, X from one individual
DE69024104T2 (de) Polypeptide und Polypeptidanaloge mit inhibitorischer Aktivität gegenüber menschlicher Elastase
CH681080A5 (enExample)
DE3650276T2 (de) Proteinreinigung.
EP0238993A2 (de) Gentechnologisch-hergestellte Aprotinin-Homologe
Paradkar et al. Affinity-based reverse micellar extraction and separation (ARMES): a facile technique for the purification of peroxidase from soybean hulls
DE3856203T2 (de) Produktion von gereinigtem, biologisch aktivem, bakteriell hergestelltem human-csf-1
DE68913251T2 (de) Verfahren zur Verringerung der Heterogenität von monoklonalen Antikörpern.
EP0510658A2 (de) Verbesserung der Ausbeute bei der Sekretion von disulfidverbrückten Proteinen
DE69032315T2 (de) Peptidyl prolyl-cis.trans-isomersae
DE69231169T2 (de) Verfahren zur Herstellung von Interleukin-6
EP0621899B1 (de) Expression signalpeptid-freier staphylokinasen
DE3852105T2 (de) Verfahren zur herstellung von aprotinin und aprotinin-homologen in hefe.
DE19629982A1 (de) Aprotinin-Varianten mit verbesserten Eigenschaften
DE69631906T2 (de) Verfahren zur herstellung von richtig gefaltetem, biologisch aktivem, rekombinantem protein

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee